Hyperinsulinism

Dasiglucagon lowers the amount of IV glucose required by more than 50% for infants with congenital hyperinsulinism, according to top-line results from a phase 3 clinical trial.

Children who are obese or overweight may be at higher risk for kidney alterations and kidney disease risk factors, a recently published cross-sectional study suggests.